Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17509778 | 0.78 | CRBN (0.33) | MAP3K14DDB1CRBN | |
| SCHEMBL3949247 | 0.77 | MAP3K14 (0.40) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL7264550 | 0.77 | MAP3K14 (0.40) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL11211758 | 0.77 | ALDH1A1 (0.33) | MAP3K14MEN1KMT2A | |
| SCHEMBL28608528 | 0.76 | MEN1 (0.40) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL7530544 | 0.76 | MAP3K14 (0.39) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL57232 | 0.76 | MAP3K14 (0.39) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL977159 | 0.74 | MAP3K14 (0.38) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL18015890 | 0.74 | MAP3K14 (0.38) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL1773976 | 0.74 | CRBN (0.40) | MAP3K14MEN1APEX1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2985286-B1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-11 | — | — | EP | claimed |
| US-9359366-B2 | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | claimed |
| US-20160052928-A1 | INTERMEDIATE OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-02-25 | — | — | US | claimed |
| EP-2985286-A1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2016-02-17 | — | — | EP | claimed |
| EP-2985286-B1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-11 | — | — | EP | disclosed |
| US-9359366-B2 | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20160052928-A1 | INTERMEDIATE OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-02-25 | — | — | US | disclosed |
| EP-2985286-A1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014160739-A2 | TRIFLUOROBORATE MASS SPECTROMETRIC TAGS | CELLMOSAIC INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20090012008-A1 | Pharmaceutical Composition for Photodynamic Therapy and a Method for Treating Oncological Diseases by Using Said Composition | VALENTIN VIKTOROVICH PETROV (RU) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052928-A1 | INTERMEDIATE OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | POR, CYP2C19, TKFC | MAP3K14 2701/4885MEN1 3336/4885APEX1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.